Education
About Us
Working with TipRanks
Follow Us
Brainsway Ltd (BWAY)
NASDAQ:BWAY
BWAY Stock Chart & Stats
$14.50
-$0.11(-1.13%)
At close: 4:00 PM EST
$14.50
-$0.11(-1.13%)
Day’s Range― - ―
52-Week Range$7.84 - $17.92
Previous CloseN/A
Volume9.67K
Average Volume (3M)71.58K
Market Cap
$301.23M
Enterprise Value$222.43M
Total Cash (Recent Filing)$70.46M
Total Debt (Recent Filing)$6.75M
Price to Earnings (P/E)43.5
Beta1.15
Next Earnings
Mar 11, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding19,560,644
10 Day Avg. Volume82,234
30 Day Avg. Volume71,578
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)2.57
Price to Sales (P/S)3.90
P/FCF Ratio24.63
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue4.53
Enterprise Value/Gross Profit6.05
Enterprise Value/Ebitda24.41
Forecast
1Y Price Target
$20.00Price Target Upside37.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.18
Revenue Forecast (FY)$51.68M
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalExpanded FDA clearance makes Deep TMS available as an adjunct therapy for adolescents aged 15-21 with major depressive disorder (MDD).
Revenue GrowthRevenue in 3Q25 increased 29% to $13.5M vs. the year-ago period.
Strategic InvestmentsBrainsWay announced four new minority equity investments in 2025, expanding strategic presence across the mental health treatment ecosystem.
Bears Say
Market RisksRisks include, but are not limited to: slower-than-projected uptake of Deep TMS systems, failure to expand reimbursement and market access, inability to advance in other indications, and possible long-term dilution risk.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $7.84 and its highest was $17.92 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $301.23M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is Mar 11, 2026 which is in 109 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Nov 11, 2025. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.047 by -$0.007.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Undervalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate is 0.05.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 19,560,644 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.04 in its last earnings report, missing expectations of $0.047. Following the earnings report the stock price went down -5.831%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BWAY
Brainsway Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (37.93% Upside)
$20.00 (37.93% Upside)
Blogger Sentiment
Bullish
BWAY Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 199.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.50%
12-Months-Change
Fundamentals
Return on Equity
11.05%
Trailing 12-Months
Asset Growth
56.81%
Trailing 12-Months
Company Description
Brainsway Ltd
Brainsway Ltd. is a medical technology company specializing in advanced non-invasive treatments for mental health disorders, primarily through its proprietary Deep Transcranial Magnetic Stimulation (dTMS) technology. The company operates in the healthcare sector with a focus on psychiatric and neurological conditions, offering innovative solutions for depression, anxiety, PTSD, and other disorders. Its core products include the dTMS devices that are used in clinical settings and are designed to enhance the efficacy of treatment protocols.
BWAY Company Deck
BWAY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
BrainsWay's Q3 2025 earnings call indicated strong growth and positive developments, including record revenue, increased system shipments, and successful strategic investments. Despite increased operating expenses and a delay in FDA clearance for Neurolief, the company's performance and raised guidance reflect a generally optimistic outlook.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$20.00
▲(37.93% Upside)
Technical Analysis
Sanuwave Health
―
Tactile Systems Technology
―
Viemed Healthcare
―
TriSalus Life Sciences
―
NeuroPace
―
Ownership Overview
―
Insiders
0.84% Mutual Funds
19.88% Other Institutional Investors
78.55% Public Companies and
Individual Investors